LPCNLipocine Inc.vs its industry peers
A metric-by-metric comparison of Lipocine Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LPCN본 종목 | $17M#8 | — | 0.8x#3 | 8.8x#4 | -82.3%#7 | -96400.0%#16 | -524.7%#4 | -44.2%#4 | -52.6%#1 | — | -26.6%#5 | — |
| RKTO | $20M#2 | — | 2.4x#9 | — | — | -52.3%#14 | — | -152.0%#9 | — | — | -53.6%#9 | — |
| MRKR | $20M#3 | — | 1.6x#5 | 5.5x#2 | -46.2%#6 | -13.3%#8 | -363.5%#3 | -100.0%#7 | -1413.6%#6 | — | 18.6%#2 | — |
| SHPH | $20M#1 | 349.0x#5 | 6.1x#15 | — | — | -28.2%#10 | — | -350.3%#14 | -507.7%#4 | — | -90.3%#13 | — |
| ALLR | $19M#4 | 0.0x#1 | 5.4x#13 | 59.7x#7 | — | 54.2%#1 | -3939.1%#6 | -317.6%#13 | — | — | -18.9%#3 | — |
| BFRI | $18M#5 | — | 3.1x#10 | 0.4x#1 | 11.7%#3 | 40.7%#2 | -27.2%#1 | -176.9%#10 | -712.4%#5 | — | 41.5%#1 | — |
| ARTL | $18M#6 | — | 3.6x#12 | — | — | -31.1%#11 | — | -257.7%#12 | — | — | -97.0%#15 | — |
| PTN | $18M#7 | 89.5x#4 | 1.7x#6 | — | -100.0%#9 | -41.8%#12 | — | 163.3%#2 | -2281.5%#7 | — | — | — |
| KTTA | $16M#9 | — | 0.3x#2 | 33.7x#5 | 3130.4%#1 | -46.9%#13 | -4286.7%#7 | -41.0%#3 | — | — | -33.4%#6 | — |
| CTXR | $16M#10 | — | 0.2x#1 | 180.5x#9 | 0.0%#5 | -0.8%#6 | -42806.2%#9 | -59.7%#5 | — | — | -49.9%#8 | — |
| LSTA | $16M#11 | — | 1.9x#8 | 94.3x#8 | -83.0%#8 | 17.0%#5 | -10711.2%#8 | -201.2%#11 | — | 3#1 | -22.3%#4 | — |
| CYCN | $16M#12 | — | 3.1x#11 | 7.6x#3 | 3.7%#4 | -15.4%#9 | -239.8%#2 | -69.4%#6 | -69.1%#2 | — | -77.9%#11 | — |
| ANEB | $15M#13 | — | 1.9x#7 | — | — | -3.5%#7 | — | -106.9%#8 | — | — | -85.1%#12 | — |
| MBRX | $15M#14 | 0.1x#3 | 1.3x#4 | — | — | 28.8%#4 | — | 289.6%#1 | — | — | -92.5%#14 | — |
| HIND | $14M#15 | 0.0x#2 | 5.6x#14 | 44.6x#6 | 24.4%#2 | -609.0%#15 | -3269.4%#5 | -405.7%#15 | -226.2%#3 | — | -72.9%#10 | — |
| ADIL | $14M#16 | — | — | — | — | 39.5%#3 | — | — | — | — | -40.1%#7 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice